Recombinant COVID-19 monovalent XBB.1.5 Protein Vaccine (Chengdu WestVac)

新冠病毒单价XBB.1.5重组蛋白疫苗(成都威斯克)

Report date: 2025/07/08 13:31:55

Base Information

Drug NameRecombinant COVID-19 monovalent XBB.1.5 Protein Vaccine (Chengdu WestVac)

Drug Alias NameRecombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)(Chengdu WestVac)重组新冠病毒(XBB变异株)三聚体蛋白疫苗 (S9细胞)(成都威斯克)重组新冠病毒(XBB变异株)三聚体蛋白疫苗(Sf9细胞)(成都威斯克)威克欣WSK-V102D

ClassificationVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)

Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)

Original Approved Country/TerritoryMainland China

Original Approved Date2023/06/01

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesChengdu WestVac Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesChengdu WestVac Biopharma Co Ltd

Inactive CompaniesWestVac Biopharma (Guangzhou) Co Ltd

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A